ADRB2 and prostate cancer: Activation of β2-AR signaling induces phosphorylation of PKA substrates CREB, vasodilator-stimulated phosphoprotein (VASP), Bcl-2 antagonist of cell death (BAD) and increases expression of myeloid cell leukemia 1 (MCL-1), leading to inhibition of apoptosis in prostate cancer [147].